1.915

0.00% 0.005

Proqr Therapeutics N V (PRQR)

Overview News Price History Option Chain Discussions Forecast

Proqr Therapeutics N V stock is traded at $1.915, with a volume of 489.94K. It is up +0.00% in the last 24 hours and up +12.94% over the past month. ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

Previous Close:

$1.92

Open:

$1.91

24h Volume:

489.94K

Relative Volume:

0.51

Market Cap:

$270.25M

Revenue:

$15.53M

Net Income/Loss:

$-52.71M

P/E Ratio:

-3.8109

EPS:

-0.5025

Net Cash Flow:

$-59.00M

1W Performance:

+6.08%

1M Performance:

+12.94%

6M Performance:

+32.41%

1Y Performance:

-6.34%

1-Day Range:

$1.90

$2.00

1-Week Range:

$1.79

$2.00

52-Week Range:

$1.33

$3.10

Proqr Therapeutics N V Stock (PRQR) Company Profile

Name

Proqr Therapeutics N V

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

Address

Employee

187

Twitter

@proqr

Next Earnings Date

2026-08-20

Latest SEC Filings

PRQR's Discussions on Twitter

Compare PRQR vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRQR Proqr Therapeutics N V	1.915	270.95M	15.53M	-52.71M	-59.00M	-0.5025
VRTX Vertex Pharmaceuticals Inc	515.89	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.79	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.63	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.22	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.16	39.31B	5.76B	514.49M	1.10B	4.4813

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	Oppenheimer	Outperform
Apr-29-25	Resumed	Cantor Fitzgerald	Overweight
Apr-29-25	Initiated	Evercore ISI	Outperform
Mar-10-25	Upgrade	Citigroup	Neutral → Buy
Jan-10-25	Initiated	Oppenheimer	Outperform
Oct-29-24	Upgrade	Raymond James	Outperform → Strong Buy
Nov-08-23	Upgrade	Chardan Capital Markets	Neutral → Buy
Mar-30-23	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Dec-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-14-22	Downgrade	Citigroup	Buy → Neutral
Feb-11-22	Downgrade	Raymond James	Strong Buy → Mkt Perform
Feb-11-22	Downgrade	Stifel	Buy → Hold
Feb-01-22	Initiated	Raymond James	Strong Buy
May-03-21	Initiated	Stifel	Buy
Mar-25-21	Reiterated	Citigroup	Buy
Nov-03-20	Resumed	Cantor Fitzgerald	Overweight
Mar-12-19	Reiterated	Chardan Capital Markets	Buy
Dec-19-18	Initiated	RBC Capital Mkts	Outperform
Nov-15-18	Initiated	Citigroup	Buy
Sep-19-18	Initiated	Evercore ISI	Outperform
Sep-26-17	Reiterated	JMP Securities	Mkt Outperform
Jun-20-16	Initiated	Chardan Capital Markets	Neutral
Oct-15-14	Initiated	Deutsche Bank	Buy
Oct-13-14	Initiated	H.C. Wainwright	Buy

View All

Proqr Therapeutics N V Stock (PRQR) Latest News

07:46 AM

H.C. Wainwright reiterates ProQR stock rating on platform data By Investing.com - Investing.com India

07:46 AM

07:40 AM

H.C. Wainwright reiterates ProQR stock rating on platform data - Investing.com

07:40 AM

Aug 15, 2026

ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Hold at Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 14, 2026

ProQR Therapeutics NV earnings beat by €0.03, revenue topped estimates - Investing.com Nigeria

Aug 14, 2026

Aug 13, 2026

ProQR Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 13, 2026

ProQR Therapeutics NV reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

ProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 Results - TipRanks

Aug 13, 2026

ProQR Therapeutics Reports First Clinical Validation of Axiomer RNA Editing Platform, Positive AX-0810 Data and Upcoming Pipeline Milestones - Quiver Quantitative

Aug 13, 2026

ProQR Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 13, 2026

Aug 11, 2026

ProQR Therapeutics NV expected to post a loss of 11 cents a shareEarnings Preview - TradingView

Aug 11, 2026

Aug 07, 2026